U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C23H37N5O4S2
Molecular Weight 511.701
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of LITRONESIB

SMILES

CCNCCS(=O)(=O)NC[C@]1(SC(NC(=O)C(C)(C)C)=NN1C(=O)C(C)(C)C)C2=CC=CC=C2

InChI

InChIKey=YVAFBXLHPINSIK-QHCPKHFHSA-N
InChI=1S/C23H37N5O4S2/c1-8-24-14-15-34(31,32)25-16-23(17-12-10-9-11-13-17)28(19(30)22(5,6)7)27-20(33-23)26-18(29)21(2,3)4/h9-13,24-25H,8,14-16H2,1-7H3,(H,26,27,29)/t23-/m0/s1

HIDE SMILES / InChI

Molecular Formula C23H37N5O4S2
Molecular Weight 511.701
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 1 / 1
E/Z Centers 0
Optical Activity UNSPECIFIED

Litronesib is a specific, ATP-uncompetitive, allosteric, and potent small-molecule inhibitor of Eg5 with potential antineoplastic activity. Litronesib selectively inhibits the activity of Eg5, which may result in mitotic disruption, apoptosis and consequently cell death in tumor cells that are actively dividing. Histone-H3 phosphorylation of tumor and proliferating skin cells is a promising pharmacodynamic biomarker for in vivo anticancer activity of litronesib. Litronesib had been in phase I clinical trial for the treatment of solid tumors. The most frequent-related adverse events were hematologic such as neutropenia.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: P52732
Gene ID: 3832.0
Gene Symbol: KIF11
Target Organism: Homo sapiens (Human)
PubMed

PubMed

TitleDatePubMed
Investigation of the mechanism of racemization of litronesib in aqueous solution: unexpected base-catalyzed inversion of a fully substituted carbon chiral center.
2014 Sep
A Novel Eg5 Inhibitor (LY2523355) Causes Mitotic Arrest and Apoptosis in Cancer Cells and Shows Potent Antitumor Activity in Xenograft Tumor Models.
2015 Nov
Two Phase 1 dose-escalation studies exploring multiple regimens of litronesib (LY2523355), an Eg5 inhibitor, in patients with advanced cancer.
2017 Feb
Crystal structure of the Eg5 - K858 complex and implications for structure-based design of thiadiazole-containing inhibitors.
2018 Aug 5
Patents

Patents

Sample Use Guides

Days 1, 2, and 3 every 3 weeks at dose level - 5 mg/m²/day
Route of Administration: Intravenous
Substance Class Chemical
Created
by admin
on Fri Dec 15 16:04:56 GMT 2023
Edited
by admin
on Fri Dec 15 16:04:56 GMT 2023
Record UNII
6611F8KYCV
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
LITRONESIB
INN   USAN   WHO-DD  
USAN   INN  
Official Name English
LY-2523355
Code English
LY 2523355
Code English
PROPANAMIDE, N-(4-(2,2-DIMETHYL-1-OXOPROPYL)-5-((((2-(ETHYLAMINO)ETHYL)SULFONYL)AMINO)METHYL)-4,5-DIHYDRO-5-PHENYL-1,3,4-THIADIAZOL-2-YL)-2,2-DIMETHYL-, (5R)-
Common Name English
KF89617
Code English
Litronesib [WHO-DD]
Common Name English
KF-89617
Code English
(-)-N-(4-(2,2-DIMETHYLPROPANOYL)-5-((((2-(ETHYLAMINO)ETHYL)SULFONYL)AMINO)METHYL)-5- PHENYL-4,5-DIHYDRO-1,3,4-THIADIAZOL-2-YL)-2,2-DIMETHYLPROPANAMIDE
Systematic Name English
LY2523355
Code English
PROPANAMIDE, N-(4-(2,2-DIMETHYL-1-OXOPROPYL)-5-((((2-(ETHYLAMINO)ETHYL)SULFONYL) AMINO)METHYL)-4,5-DIHYDRO-5-PHENYL-1,3,4-THIADIAZOL-2-YL)-2,2-DIMETHYL-, (-)-
Common Name English
N-(4-(2,2-DIMETHYLPROPIONYL)-(5R)-5-((2-ETHYLAMINO-ETHANESULFONYLAMINO)METHYL)-5-PHENYL-4,5-DIHYDRO-(1,3,4)THIADIAZOL-2-YL)-2,2-DIMETHYLPROPIONAMIDE
Systematic Name English
LITRONESIB [USAN]
Common Name English
KF 89617
Code English
(R)-N-(4-(2,2-DIMETHYL-PROPIONYL)-5-((2-ETHYLAMINO-ETHANESULFONYLAMINO)-METHYL)-5- PHENYL-4,5-DIHYDRO-(1,3,4)THIADIAZOL-2-YL)-2,2-DIMETHYL-PROPIONAMIDE
Systematic Name English
litronesib [INN]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C67440
Created by admin on Fri Dec 15 16:04:56 GMT 2023 , Edited by admin on Fri Dec 15 16:04:56 GMT 2023
Code System Code Type Description
CAS
910634-41-2
Created by admin on Fri Dec 15 16:04:56 GMT 2023 , Edited by admin on Fri Dec 15 16:04:56 GMT 2023
PRIMARY
INN
9159
Created by admin on Fri Dec 15 16:04:56 GMT 2023 , Edited by admin on Fri Dec 15 16:04:56 GMT 2023
PRIMARY
FDA UNII
6611F8KYCV
Created by admin on Fri Dec 15 16:04:56 GMT 2023 , Edited by admin on Fri Dec 15 16:04:56 GMT 2023
PRIMARY
SMS_ID
100000126302
Created by admin on Fri Dec 15 16:04:56 GMT 2023 , Edited by admin on Fri Dec 15 16:04:56 GMT 2023
PRIMARY
USAN
UU-77
Created by admin on Fri Dec 15 16:04:56 GMT 2023 , Edited by admin on Fri Dec 15 16:04:56 GMT 2023
PRIMARY
DRUG BANK
DB11861
Created by admin on Fri Dec 15 16:04:56 GMT 2023 , Edited by admin on Fri Dec 15 16:04:56 GMT 2023
PRIMARY
PUBCHEM
25167017
Created by admin on Fri Dec 15 16:04:56 GMT 2023 , Edited by admin on Fri Dec 15 16:04:56 GMT 2023
PRIMARY
EVMPD
SUB33348
Created by admin on Fri Dec 15 16:04:56 GMT 2023 , Edited by admin on Fri Dec 15 16:04:56 GMT 2023
PRIMARY
ChEMBL
CHEMBL2105661
Created by admin on Fri Dec 15 16:04:56 GMT 2023 , Edited by admin on Fri Dec 15 16:04:56 GMT 2023
PRIMARY
NCI_THESAURUS
C88328
Created by admin on Fri Dec 15 16:04:56 GMT 2023 , Edited by admin on Fri Dec 15 16:04:56 GMT 2023
PRIMARY
Related Record Type Details
TARGET -> INHIBITOR
IC50
Related Record Type Details
ACTIVE MOIETY